Market Cap 438.31B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.52
Forward PE 17.37
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,246,700
Avg Vol 7,151,912
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 20%
Beta 0.30
Analysts Strong Sell
Price Target $257.76

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 14 at 7:00 PM
$SLS BAT / FDA Approved in 2018 - is a well known - Failed Maintenance Treatment... Ven+Aza BAT for the SLS P3 CONTROL ARM, FAILED the VIALE-M Phase 3 CR1 / First Remission Maintenance Trial conducted by $ABBV Ven Aza also Failed the SLS Phase 3 Control Arm, Second Remission Patients. It is not complicated --- just look at the Market Cap./Share Price, Cash, Numbers of Funds Invested - all up 1,000% or more Since the Interim Analysis - where the IDMC UNBLINDED Actual Phase 3 MOS and IR Data ... that told all the AML Market Participants.
0 · Reply
wyoming2020
wyoming2020 Jul. 14 at 6:02 PM
$VKTX my view only I think this is a great all share or part share acquisition target for $JNJ $NVO or $ABBV
0 · Reply
GettnFibbywIT
GettnFibbywIT Jul. 14 at 4:26 PM
$XLV $SPY $LLY $ABBV $JNJ The Healthcare Sector vs S&P 500 (XLV/SPY) relative strength ratio remains structurally challenged. The ratio continues to exhibit a pattern of lower highs, with three declining relative-strength peaks since March 2026. While Healthcare has recently improved on an absolute basis, the relative-strength trend suggests the move remains a counter-trend advance rather than evidence of sustained sector leadership versus the S&P 500:
0 · Reply
TalkMarkets
TalkMarkets Jul. 14 at 4:21 PM
SMID Biotech Stocks Were Cruising To New Highs Until Friday’s Speed Bump $ABBV $ADPT $AMRX $ARKG $BAX https://talkmarkets.com/article/smid-biotech-stocks-were-cruising-to-new-highs-until-fridays-speed-bump-1784045167
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 3:51 PM
$BIIB sellogen and buy $ABBV or $AMGN
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 2:55 PM
$ABBV added ahead of Ex-Div day
0 · Reply
Wallstfan
Wallstfan Jul. 14 at 2:54 PM
$ABBV added more on ex dividend day!
0 · Reply
Oldpuck
Oldpuck Jul. 14 at 2:23 PM
$ABBV Giving it all back
1 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Jul. 14 at 1:46 PM
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb: https://www.fool.com/investing/2026/07/14/donald-trumps-drug-pricing-deals-are-reshaping-big/ $PFE $ABBV $BMY
0 · Reply
Latest News on ABBV
AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 1 day ago

AbbVie price target raised to $260 from $230 at UBS


AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 4 days ago

AbbVie price target raised to $280 from $260 at RBC Capital


AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 4 days ago

AbbVie price target raised to $276 from $234 at BofA


AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 4 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo


AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 5 days ago

AbbVie price target raised to $280 from $260 at JPMorgan


AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 5 days ago

AbbVie price target raised to $261 from $249 at Guggenheim


AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 8 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c


AbbVie price target raised to $300 from $275 at HSBC

2026-07-06T14:20:07.000Z - 8 days ago

AbbVie price target raised to $300 from $275 at HSBC


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 18 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 20 days ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 22 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 22 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 22 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 22 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 22 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 22 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 26 days ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 6 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 14 at 7:00 PM
$SLS BAT / FDA Approved in 2018 - is a well known - Failed Maintenance Treatment... Ven+Aza BAT for the SLS P3 CONTROL ARM, FAILED the VIALE-M Phase 3 CR1 / First Remission Maintenance Trial conducted by $ABBV Ven Aza also Failed the SLS Phase 3 Control Arm, Second Remission Patients. It is not complicated --- just look at the Market Cap./Share Price, Cash, Numbers of Funds Invested - all up 1,000% or more Since the Interim Analysis - where the IDMC UNBLINDED Actual Phase 3 MOS and IR Data ... that told all the AML Market Participants.
0 · Reply
wyoming2020
wyoming2020 Jul. 14 at 6:02 PM
$VKTX my view only I think this is a great all share or part share acquisition target for $JNJ $NVO or $ABBV
0 · Reply
GettnFibbywIT
GettnFibbywIT Jul. 14 at 4:26 PM
$XLV $SPY $LLY $ABBV $JNJ The Healthcare Sector vs S&P 500 (XLV/SPY) relative strength ratio remains structurally challenged. The ratio continues to exhibit a pattern of lower highs, with three declining relative-strength peaks since March 2026. While Healthcare has recently improved on an absolute basis, the relative-strength trend suggests the move remains a counter-trend advance rather than evidence of sustained sector leadership versus the S&P 500:
0 · Reply
TalkMarkets
TalkMarkets Jul. 14 at 4:21 PM
SMID Biotech Stocks Were Cruising To New Highs Until Friday’s Speed Bump $ABBV $ADPT $AMRX $ARKG $BAX https://talkmarkets.com/article/smid-biotech-stocks-were-cruising-to-new-highs-until-fridays-speed-bump-1784045167
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 3:51 PM
$BIIB sellogen and buy $ABBV or $AMGN
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 2:55 PM
$ABBV added ahead of Ex-Div day
0 · Reply
Wallstfan
Wallstfan Jul. 14 at 2:54 PM
$ABBV added more on ex dividend day!
0 · Reply
Oldpuck
Oldpuck Jul. 14 at 2:23 PM
$ABBV Giving it all back
1 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Jul. 14 at 1:46 PM
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb: https://www.fool.com/investing/2026/07/14/donald-trumps-drug-pricing-deals-are-reshaping-big/ $PFE $ABBV $BMY
0 · Reply
jbh973
jbh973 Jul. 14 at 1:06 PM
I didn't spend the past 43 yrs of my life living in Beaconsfield, Iowa (Pop.15) carving out a career delivering the local paper ''Corn & Stuff'' w/o learning a thing or two & since I can't work today because someone stole the basket off my bike again, most likely those Conroy brothers over in Ellston, they're are really scamps & scoundrels, the whole lot of em. So, it's whittling away I give u THE PRE STOCK MARKET REVIEW ( The A full moon makes for a well lit street Edition ) $NGEN Mabel Bailey endorsed this one in last weeks paper in her byline ''Stock tips & Toaster Shakins''. Since she was the one who told me never mistake a bull for a cow when u go a milking, I'd listen to her. $LKNCY We know corn as much as the Chinese know ric...err...coffee. $ABBV Mayor Ed Mobley owns 2 horses & pays his mortgage with the dividends from this beauty. $BURU The whole town chipped in last month & bought 8 shares. $SPCX If they can use hay for fuel we'd be happy to trade some for shares. 😀
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 13 at 6:21 PM
$ABBV $MRK $PFE $SLS $LLY One drug company just spent more buying up rivals than every other big drugmaker on the planet combined. Eli Lilly, now the world's most valuable pharmaceutical company, spent about $25 billion acquiring smaller biotech companies in the first six months of this year. The other eleven largest drugmakers spent roughly $21 billion between all of them. Lilly alone outspent the entire rest of the top tier. SLS Next Up! ✌️🙏❤️‍🩹
0 · Reply
msgetzoff
msgetzoff Jul. 13 at 4:27 PM
$ABBV ....such a mercurial stock.
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jul. 13 at 12:22 PM
$MRK $SLS $PFE $ABBV Part 3. Last official PR 2 months ago. All SEC filings during the last 2 months point to an Outright BO. Only thing left to see here is BO before or after the GPS Regal Pivotal Registrational Phase 3 study Breakthrough data. News will hit in waves soon! ✌️🙏❤️‍🩹
0 · Reply
DailyWatcher_
DailyWatcher_ Jul. 13 at 10:57 AM
$MRK position initiated near the breakout retest zone. Holding the $121$122.80 area could reopen a move toward $124.70, with $130.20 becoming the next technical objective if momentum continues. Clean breakout retest or failed breakout? Also watching $LLY, $ABBV, and $JNJ as large-cap healthcare names continue to attract institutional attention. Relative strength across the group could provide additional confirmation for the next move. The next setup is already taking shape. Stay connected. Visit my profile for more market insights, trade ideas, and high-conviction stock setups.
0 · Reply
p3akyblinder
p3akyblinder Jul. 13 at 12:12 AM
$MLTX It’s very clear that the SLS crowd lacks biotech/investing literacy… hope it works out for them but they’re likely in for a rude awakening. $MRK $ABBV $LLY $SNY will all be MoonLake suitors soon imho GLTA
4 · Reply
HboFam
HboFam Jul. 12 at 8:21 PM
$MRK is just waiting, like all of us for the imminent Gps p3 trial results before buying SLS Gps and Pembro results in PROC is better than Elahere $IMGN which got fda approved and bought for 16.4 months $ABBV https://www.biospace.com/sellas-life-sciences-presents-positive-key-immunobiological-and-clinical-data-from-phase-1-2-trial-of-galinpepimut-s-gps-in-combination-with-keytruda-in-wt1-platinum-resistant-advanced-ovarian-cancer-at-the-igcs-2023-annual-global-meeting
0 · Reply
p3akyblinder
p3akyblinder Jul. 12 at 7:23 PM
$MLTX Bidding war will involve $ABBV for certain. Skyrizi is their most valuable cash cow and brought in 18B last year across PsA (our incoming data), Ulcerative colitis, and Crohn’s disease. If IZAR-1 shows best-in-class efficacy in PsA, AbbVie will step in quickly and compete against $LLY . Merck wants SLK for HS alone, so a win in PsA will force them to overpay if they don’t want to get knocked out of the running. Will be a very exciting few months ahead if SLK replicates our HS win in PsA.
0 · Reply
KingTrades09
KingTrades09 Jul. 12 at 2:27 PM
$ABBV nive breakout but with bios rally coming to halt, this might retest the breakout and then 300 soon
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 12 at 8:26 AM
$ABBV AbbVie Inc. (NYSE: ABBV) combines biotech innovation with reliable cash flow, making it one of the strongest healthcare stocks on the market. Discover why its leadership in immunology, oncology, biologics, and dividend growth continues to attract long-term investors. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-good-dividend-stock-to-buy-right-now/
0 · Reply
InItToWinIt100
InItToWinIt100 Jul. 12 at 5:35 AM
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty $ABBV https://apple.news/AENwmKZ6KRN-I8FbS1GjQwQ
0 · Reply
10xorbust
10xorbust Jul. 12 at 2:40 AM
$ABBV $SLS @HboFam I see you’re in damage control mode now that I caught you in a material misstatement (whether negligent or intentional). Instead of admitting your mistake, you double down on it. It is beyond dispute that the manufacturer halted the efficacy portion of VIALE-M for slow accrual. That is clearly and unmistakably documented in the medical literature. Clearly, that reflects very poorly on these BAT drugs and is quite harmful for the bears’ theory that BAT is indeed the reason why the patients in Regal are living so long - a theory I have always disputed. I strongly believe that reason is GPS. I’ve always maintained the super BAT argument is ludicrous, and that what happened in VIALE-M is supportive of that. Obviously if Ven/Aza were such a big success somehow the manufacturer would’ve made it right and would’ve come out with the efficacy branch of VIALE-M. But I also don’t want to misstate the reasons that are in the medical literature as to why the efficacy portion of VIALE-M was halted (the safety portion was completed with finding published earlier this year). If that study’s IDMC halted it for futility that’s what it would say in the literature. The record doesn’t reflect that. So I will never overstate the record and misrepresent the medical literature to people here. Let investors make their own conclusions based on what the record actually states. I can certainly give them my opinion, which is that the lead BAT arm drugs, Ven and Aza, do not work for AML remission maintenance, which have I said repeatedly. But I’m not going to misrepresent the reason for the discontinuance of the effficacy branch of VIALE-M just because I have a $1 million investment in this stock and therefore feel the need to misrepresent and potentially commit securities fraud to enrich myself. No one should. I’ll leave that to others who might want a date with the SEC, FBI and in federal court. I prefer to have a clear conscience and sleep at night. Bottom line - the halting of the efficacy branch of VIALE-M is bullish for the GPS arm in Regal. The stated reason was slow patient accrual - not futility. The IDMC made no such determination in VIALE-M. And I absolutely believe if those drugs (Ven/Aza) were effective in maintaining remission in AML, the manufacturer would have solved the issue of slow patient accrual, but chose not to.
2 · Reply